This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hunt, K. J. Articles by Kaaks, R. Search for Related Content PubMed PubMed Citation Articles by Hunt, K. J. Articles by Kaaks, R.

Insulin-like Growth Factor II and Colorectal Cancer Risk in Women

International Agency for Research on Cancer, 69372 Lyon Cedex 08, France [K. J. H., A. L., S. R., E. R., R. K.]; New York University School of Medicine, Departments of Obstetrics & Gynecology [P. T., A. A.] and Environmental Medicine [A. Z-J., R. E. S.], New York, New York 10016; Central Laboratory for Biochemistry, Hôpital de l’Antiquaille, rue de l’Antiquaille, 69321 Lyon Cedex 05, France [H. D.]; and University of Texas Health Science Center, Division of Clinical Epidemiology, San Antonio, Texas 78229 [K. J. H.]

Recently, a number of prospective studies showed evidence that the growth hormone/insulin-like growth factor I (IGF-I) axis may be important in the development of colorectal cancer. However, only a few studies have reported on the possible relationship of colorectal cancer risk with circulating levels of IGF-II, which are not growth hormone dependent and which do not vary with alterations in energy balance. In a case-control study of 102 cases and 200 matched controls nested within a cohort of 14,275 women in New York, we examined the relationship between colorectal cancer risk and prediagnostic serum levels of IGF-II. Conditional logistic regression analysis showed an odds ratio (OR) for colorectal cancer of 2.02 (95% confidence interval (CI): 0.83–4.93), comparing the upper to lower quintile of IGF-II. This association was slightly attenuated after excluding IGF-II measurements in serum samples taken within 1 year before case diagnosis (OR of 1.81; 95% CI: 0.71–4.64) and moderately attenuated after excluding IGF-II measurements in serum samples taken within 2 years before case diagnosis (OR of 1.47; 95% CI: 0.56–3.91). Adjustment for IGF-1, IGF binding protein (BP)-1, IGFBP-3, smoking, or body mass index did not substantially alter the association, whereas adjustment for IGFBP-2 moderately attenuated the relationship. Our results confirm those of three recent case-control studies, and collectively these results suggest a possible increase in colorectal cancer risk among subjects with comparatively elevated serum IGF-II. Mechanisms that might cause the increase in IGF-II levels are unknown but may include loss of parental imprinting of the IGF-II gene.

This article has been cited by other articles:

				C. S. Fuchs, R. M. Goldberg, D. J. Sargent, J. A. Meyerhardt, B. M. Wolpin, E. M. Green, H. C. Pitot, and M. Pollak Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741 Clin. Cancer Res., December 15, 2008; 14(24): 8263 - 8269. [Abstract] [Full Text] [PDF]

				R. Zhao, M. Berho, J. Nogueras, D. Sands, E. Weiss, S. Wexner, F. M. Giardiello, and M. Cruz-Correa Positive Correlation of Insulin-Like Growth Factor-II with Proliferating Cell Index in Patients with Colorectal Neoplasia Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1819 - 1822. [Abstract] [Full Text] [PDF]

				J. A. Meyerhardt, J. A. Sloan, D. J. Sargent, R. M. Goldberg, M. Pollak, R. F. Morton, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, and C. S. Fuchs Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1402 - 1410. [Abstract] [Full Text] [PDF]

				D. W. Voskuil, A. Vrieling, L. J. van't Veer, E. Kampman, and M. A. Rookus The Insulin-like Growth Factor System in Cancer Prevention: Potential of Dietary Intervention Strategies Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 195 - 203. [Abstract] [Full Text] [PDF]

				M. S. Sandhu, J. M. Gibson, A. H. Heald, D. B. Dunger, and N. J. Wareham Association between Insulin-Like Growth Factor-I: Insulin-Like Growth Factor-Binding Protein-1 Ratio and Metabolic and Anthropometric Factors in Men and Women Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 166 - 170. [Abstract] [Full Text] [PDF]

				D. Gunnell, S. E. Oliver, J. L. Donovan, T. J. Peters, D. Gillatt, R. Persad, F. C. Hamdy, D. E. Neal, and J. M. P. Holly Do Height-Related Variations in Insulin-Like Growth Factors Underlie the Associations of Stature with Adult Chronic Disease? J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 213 - 218. [Abstract] [Full Text] [PDF]

				G. S. Howarth Insulin-Like Growth Factor-I and the Gastrointestinal System: Therapeutic Indications and Safety Implications J. Nutr., July 1, 2003; 133(7): 2109 - 2112. [Abstract] [Full Text] [PDF]